
Sign up to save your podcasts
Or
Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.
4.5
1010 ratings
Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.
13 Listeners
23 Listeners
87 Listeners
62 Listeners
2 Listeners
55 Listeners
10 Listeners
1 Listeners
6 Listeners
18 Listeners
23 Listeners
26 Listeners
1 Listeners
3 Listeners
335 Listeners
3 Listeners
28 Listeners
20 Listeners
9 Listeners
35 Listeners
2 Listeners
55 Listeners
42 Listeners
6 Listeners
13 Listeners
20 Listeners
0 Listeners
10 Listeners
11 Listeners